Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: friboulet l. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC. Friboulet L, et al. Clin Cancer Res. 2011 Sep 1;17(17):5562-72. doi: 10.1158/1078-0432.CCR-11-0790. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750204
PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA, Adam J, Vanhecke E, Vielh P, Pirker R, Friboulet L, Popper H, Robin A, Commo F, Thomale J, Kayitalire L, Filipits M, Le Chevalier T, André F, Brambilla E, Soria JC. Olaussen KA, et al. Among authors: friboulet l. Lung Cancer. 2013 May;80(2):216-22. doi: 10.1016/j.lungcan.2013.01.014. Epub 2013 Feb 12. Lung Cancer. 2013. PMID: 23410825
ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.
Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, André F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC. Friboulet L, et al. N Engl J Med. 2013 Mar 21;368(12):1101-10. doi: 10.1056/NEJMoa1214271. N Engl J Med. 2013. PMID: 23514287 Free PMC article.
19q13-ERCC1 gene copy number increase in non--small-cell lung cancer.
Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, Goubar A, Li Y, Robin A, Behrens C, Commo F, Validire P, André F, Wistuba II, Soria JC, Olaussen KA. Vanhecke E, et al. Among authors: friboulet l. Clin Lung Cancer. 2013 Sep;14(5):549-57. doi: 10.1016/j.cllc.2013.01.006. Epub 2013 Jun 15. Clin Lung Cancer. 2013. PMID: 23773262
ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform.
Friboulet L, Postel-Vinay S, Sourisseau T, Adam J, Stoclin A, Ponsonnailles F, Dorvault N, Commo F, Saulnier P, Salome-Desmoulez S, Pottier G, André F, Kroemer G, Soria JC, Olaussen KA. Friboulet L, et al. Cell Cycle. 2013 Oct 15;12(20):3298-306. doi: 10.4161/cc.26309. Epub 2013 Sep 9. Cell Cycle. 2013. PMID: 24036546 Free PMC article.
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA. Friboulet L, et al. Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27. Cancer Discov. 2014. PMID: 24675041 Free PMC article.
Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, Engelman JA, Fujita N. Katayama R, et al. Among authors: friboulet l. Clin Cancer Res. 2015 Jan 1;21(1):166-74. doi: 10.1158/1078-0432.CCR-14-1385. Epub 2014 Oct 28. Clin Cancer Res. 2015. PMID: 25351743 Free PMC article.
64 results